Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

59 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI).
Janetzki S, Panageas KS, Ben-Porat L, Boyer J, Britten CM, Clay TM, Kalos M, Maecker HT, Romero P, Yuan J, Kast WM, Hoos A; Elispot Proficiency Panel of the CVC Immune Assay Working Group. Janetzki S, et al. Cancer Immunol Immunother. 2008 Mar;57(3):303-15. doi: 10.1007/s00262-007-0380-6. Epub 2007 Aug 25. Cancer Immunol Immunother. 2008. PMID: 17721781 Free PMC article.
Guidelines for the automated evaluation of Elispot assays.
Janetzki S, Price L, Schroeder H, Britten CM, Welters MJ, Hoos A. Janetzki S, et al. Nat Protoc. 2015 Jul;10(7):1098-115. doi: 10.1038/nprot.2015.068. Epub 2015 Jun 25. Nat Protoc. 2015. PMID: 26110715
Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine Consortium.
Britten CM, Janetzki S, Ben-Porat L, Clay TM, Kalos M, Maecker H, Odunsi K, Pride M, Old L, Hoos A, Romero P; HLA-peptide Multimer Proficiency Panel of the CVC-CRI Immune Assay Working Group. Britten CM, et al. Among authors: janetzki s. Cancer Immunol Immunother. 2009 Oct;58(10):1701-13. doi: 10.1007/s00262-009-0681-z. Epub 2009 Mar 4. Cancer Immunol Immunother. 2009. PMID: 19259668 Free PMC article.
Toward the harmonization of immune monitoring in clinical trials: quo vadis?
Britten CM, Janetzki S, van der Burg SH, Gouttefangeas C, Hoos A. Britten CM, et al. Among authors: janetzki s. Cancer Immunol Immunother. 2008 Mar;57(3):285-8. doi: 10.1007/s00262-007-0379-z. Epub 2007 Aug 25. Cancer Immunol Immunother. 2008. PMID: 17721782 Free PMC article. No abstract available.
Response definition criteria for ELISPOT assays revisited.
Moodie Z, Price L, Gouttefangeas C, Mander A, Janetzki S, Löwer M, Welters MJ, Ottensmeier C, van der Burg SH, Britten CM. Moodie Z, et al. Among authors: janetzki s. Cancer Immunol Immunother. 2010 Oct;59(10):1489-501. doi: 10.1007/s00262-010-0875-4. Epub 2010 Jun 15. Cancer Immunol Immunother. 2010. PMID: 20549207 Free PMC article.
Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyond.
Britten CM, Janetzki S, van der Burg SH, Huber C, Kalos M, Levitsky HI, Maecker HT, Melief CJ, O'Donnell-Tormey J, Odunsi K, Old LJ, Pawelec G, Roep BO, Romero P, Hoos A, Davis MM. Britten CM, et al. Among authors: janetzki s. Cancer Immunol Immunother. 2011 Jan;60(1):15-22. doi: 10.1007/s00262-010-0940-z. Epub 2010 Nov 16. Cancer Immunol Immunother. 2011. PMID: 21080166 Free PMC article.
59 results